Nectar Lifesciences Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts more than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Nectar Lifesciences has received a Show Cause Notice (SCN) dated June 25, 2025, from the Office of Assistant Commissioner, Central GST, Derabassi, questioning a refund claim of Rs. 3.50 crore (Rs. 3,50,18,429). The refund relates to duties paid with interest for closure of advance licenses issued by DGFT, after the company could not meet export obligations for 2016-17 due to shortage or cancellation of export orders. The company believes the SCN lacks merit and plans to submit its response before the Adjudicating Authority within the prescribed timeline. If the matter is decided in the company's favour, it will receive the refund; otherwise, it will appeal to the appropriate authority.
The outcome is uncertain — best case is a Rs. 3.50 crore refund inflow, worst case is rejection and further litigation. Since the company is still in the show-cause stage and the amount is relatively small compared to typical operations, this is unlikely to have a material impact on the stock price unless the matter escalates.